Cydar Medical Announce Strategic Collaboration with Medtronic
Cambridge-based Surgical augmented intelligence company Cydar Medical has recently announced its strategic collaboration with medical device company Medtronic. Under this pilot agreement, EV Maps software, previously exclusive to Cydar, will be applied to approxmately 40 new global sites, fusing Cydar’s flagship augmented intelligence tech with the services and case support which Medtronic can provide, the aim being to collectively improve patient care.
The Cydar-owned EV Maps software is built to harness the latest in GPU (cloud graphics processing) computing, machine learning, and computer vision tech, to improve visualisation and decision making in surgical theatres and across the care spectrum in general.
This tech is designed to enable clinicians to create advanced, patient-specific 3D maps in detail, to be used for image-based navigation, procedure planning, and post-op review, resulting in a reduction of radiation exposure to both the patient and clinical team, as well as providing increased delivery confidence.
The pilot collaborative programme should also inform the future development of procedure planning, supported by the use of predictive analytics, and doing so by assessing risk factors such as endoleaks, sac regression probability, along with myriad other inidustry-related concerns.
This collaboration marks a first for a medical tech company entering into a public, strategic partnership with digital endovascular technology in order to progress advanced aortic treatment decisions for the patient, and is representative of Medtronic’s continued commitment to innovative solutions within aortic care for both physicians and service users.
Carolyn Sleeth, Vice President and general manager at Medtronic, had this to say regarding the merger:
“Medtronic aims to revolutionise endovascular aortic treatment with digital solutions with this phased approach. By collecting data across the patient journey—before, during and after procedure—our goal is to provide analytic support to make our endovascular stent grafts ‘smart’”.